|
Keynote Speaker for this Event:
|
|
The paradigm of traditional drug development is shifting as more and more biopharmaceutical organizations look to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment.
For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of prolonged study start-up times, unknown regulation and logistics requirements and political uncertainty.
During this presentation, ClinStar CEO David Passov will explore how to effectively navigate these challenges in Russia and parts of Eastern Europe (EE) and demonstrate how these countries are not only effective in rescue trials but should be included as an integral part of your initial study plans.
Mr. Passov will:
- Discuss characteristics and classification of “Emerging” vs “Emerged” for EE geographies
- Consider why Russia and parts of EE are optimal for conducting clinical trials compared to other emerging countries
- Discuss how to successfully navigate cultural differences and regulatory changes in the region in order to achieve expedited approval timelines and recruitment
- Present case studies outlining the operational and opportunity cost savings of conducting trials in these fast enrolling geographies
*************
Access to this archive is given on the understanding that you agree to the provision of your contact information to Xtalks sponsors and partners. Only primary contact information will be shared and this information will only be shared for the purposes of providing relevant offers. This registration form is an application only. Xtalks has the right to refuse access.
If you require help with your registration or have any questions you may contact Xtalks at register@xtalks.com or phone 416-977-6555, x 371.
By completing this registration form, you agree that the information you have provided is true and accurate.
(note: fields with marked "*" are required)